Redeye makes minor revisions based on the Q3 report. Ortoma continues to follow the outlined plan, and with the DePuy agreement, the upcoming 12 months are exciting. We slightly increase our fair value range and Base case to SEK14.5 per share. In connection with this report, we also changed the head analyst.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Ortoma - Following the set path

© Modular Finance, source Nordic Press Releases